Green Alpha Advisors’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$62.5K Sell
24,303
-131,743
-84% -$386K 0.04% 106
2026
Q2
$506K Sell
156,046
-4,096
-3% -$12K 0.34% 68
2026
Q1
$396K Sell
160,142
-978
-0.6% -$2.07K 0.39% 68
2025
Q4
$330K Buy
161,120
+14,708
+10% +$42.5K 0.3% 86
2025
Q3
$508K Sell
146,412
-24,370
-14% -$68K 0.49% 62
2025
Q2
$376K Sell
170,782
-13,121
-7% -$21.5K 0.36% 77
2025
Q1
$213K Buy
183,903
+72,275
+65% +$106K 0.23% 94
2024
Q4
$142K Buy
111,628
+68,295
+158% +$174K 0.11% 137
2024
Q3
$148K Buy
43,333
+13,066
+43% +$56.9K 0.12% 128
2024
Q2
$141K Sell
30,267
-15,818
-34% -$89.2K 0.11% 125
2024
Q1
$342K Buy
46,085
+163
+0.4% +$1.35K 0.25% 117
2023
Q4
$465K Sell
45,922
-31,266
-41% -$274K 0.34% 110
2023
Q3
$602K Buy
77,188
+15,343
+25% +$132K 0.46% 81
2023
Q2
$509K Buy
61,845
+3,174
+5% +$27.7K 0.33% 106
2023
Q1
$425K Sell
58,671
-984
-2% -$8.75K 0.3% 114
2022
Q4
$529K Buy
59,655
+2,857
+5% +$31.4K 0.44% 92
2022
Q3
$695K Sell
56,798
-283,146
-83% -$4.41M 0.59% 77
2022
Q2
$4.02M Buy
339,944
+291,531
+602% +$3.91M 0.92% 34
2022
Q1
$921K Buy
48,413
+12,199
+34% +$227K 0.62% 69
2021
Q4
$961K Buy
36,214
+4,552
+14% +$157K 0.65% 77
2021
Q3
$1.3M Buy
31,662
+737
+2% +$40.4K 0.9% 41
2021
Q2
$1.75M Buy
30,925
+20,372
+193% +$752K 1.19% 21
2021
Q1
$443K Buy
10,553
+4,517
+75% +$257K 0.44% 85
2020
Q4
$423K Buy
+6,036
New +$248K 0.51% 73

Other funds holding EDIT

Green Alpha Advisors's EDIT Position: Q3 2026 in Review

Green Alpha Advisors reduced its Editas Medicine (EDIT) stake by 84% in Q3 2026, selling an estimated $386K and leaving 24,303 shares worth $62.5K. The position accounts for 0.04% of the portfolio, ranked #106.

Green Alpha Advisors first reported a position in EDIT in Q4 2020 and has held it in 24 quarters since. The position peaked at $4.02M in Q2 2022. 7 funds tracked by Wall St. Rank hold EDIT as of Q3 2026.

  • Green Alpha Advisors held 24,303 shares of Editas Medicine worth $62.5K as of Q3 2026.
  • Green Alpha Advisors sold 131,743 Editas Medicine shares in Q3 2026, an estimated $386K.
  • Editas Medicine made up 0.04% of Green Alpha Advisors's portfolio in Q3 2026, its #106 holding.
  • Green Alpha Advisors first reported a position in Editas Medicine in Q4 2020 and has held it in 24 quarters since.
  • Green Alpha Advisors's Editas Medicine position peaked at $4.02M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2026.

Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.